StockNews.AI
SNTI
StockNews.AI
106 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI

1. Pomerantz LLP is investigating Senti Biosciences for potential securities fraud. 2. Enrollment stopped in SN301A trial due to dose limiting toxicities. 3. SNTI's stock fell 27.2% following adverse trial results.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The halted trial and fraud investigation represent significant operational and reputation risks.

How important is it?

The investigation by a prominent law firm highlights potential legal and financial risks for SNTI.

Why Short Term?

Immediate effects on stock price are expected due to ongoing investigations and trial setbacks.

Related Companies

CLESGNFTTRIL
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Senti and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 28, 2025, Senti issued a press release reporting that “enrollment has been stopped” in the Investigator Sponsored Trial for its solid tumor pipeline product SN301A, conducted in collaboration with Celes Therapeutics (Shanghai) Co. Ltd., “[b]ased on the observation of certain dose limiting toxicities[.]”  On this news, Senti’s stock price fell $1.36 per share, or 27.2%, to close at $3.64 per share on April 28, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News